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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the German language. The 
reading comprehension of the questionnaire was tested in 10 JIA parents and patients. The participating centres were asked 
to collect demographic and clinical data along the JAMAR questionnaire in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical vali-
dation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 319 JIA patients (2.8% systemic, 36.7% oligoarticular, 23.5% RF negative 
polyarthritis, and 37% other categories) and 100 healthy children were enrolled in eight centres. The JAMAR components 
discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. 
In conclusion, the German version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for 
use both in routine clinical practice and in clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the German parent and patient version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the German language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from August 2011 to 
August 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW); and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from the previous visit (cat-
egorical scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) sub-scales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2), and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for par-
ent proxy-report (child’s age 2–18), one for child self-
report, with the suggested age range of 7–18 years, and 
one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cul-
tural adapted in a similar language (i.e., Spanish in South 
American countries), only the probe technique was per-
formed. Reading comprehension and understanding of the 
translated questionnaires were tested in a probe sample of 
ten JIA parents and ten patients.
The participating centres were asked to collect demo-
graphic and clinical data along the JAMAR questionnaire 
in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 
100 healthy children and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
item-scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR sub-scales with 
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the six JIA core-set variables, with the addition of the par-
ent assessment of disease activity and pain by the.
Spearman’s correlation coefficients (r) [17] and the dis-
criminant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with the 
first and third quartiles and categorical data as absolute 
frequencies and percentages.
The complete German parent and patient versions of the 
JAMAR are available upon request from PRINTO.
Results
Cross‑cultural adaptation
The German JAMAR was fully cross-culturally adapted 
from the British English version with two forward and 
two backward translations with a concordance for 111/123 
translations lines (90.2%) for the parent version and 
111/120 lines (92.5%) for the child version.
In the probe technique analysis, 121/123 (98.4%) lines 
of the parent version of the JAMAR were understood by 
at least 80% of the ten parents tested (median = 100%; 
range 40–100%); 114/120 (95%) lines of the patient ver-
sion of the JAMAR were understood by at least 80% of 
the children (median = 100%; range 40–100%). Lines 51 
and 52 were modified according to parents’ indications; 
lines 1, 40, 49, 50, 51, and 116 were modified according 
to patients’ indications.
Demographic and clinical characteristics 
of the subjects
A total of 322 JIA patients and 100 healthy children (total 
of 422 subjects) were enrolled at eight paediatric rheuma-
tology centres. Three patients did not give the consent to 
use their data.
In the remaining 319/322 (99.1%) JIA subjects, the 
JIA categories were 2.8% with systemic arthritis, 36.7% 
with oligoarthritis, 23.5% with RF negative polyarthritis, 
3.1% with RF positive polyarthritis, 5.6% with psoriatic 
arthritis, 20.4% with enthesitis-related arthritis, and 7.8% 
with undifferentiated arthritis (Table 1). The distribution 
of JIA categories resembles the distribution of national 
cohorts [19].
A total of 413/422 (97.9%) subjects had the parent 
version of the JAMAR completed by a parent (314 from 
parents of JIA patients and 99 from parents of healthy 
children). The JAMAR was completed by 362/413 (87.7%) 
mothers and 51/413 (12.3%) fathers. The child version of 
the JAMAR was completed by 385/422 (84.1%) children 
age 5.0 or older. In addition, patients younger than 7 years, 
capable to assess their personal condition and able to read 
and write, were asked to fill in the patient version of the 
questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartiles)] obtained for the PF, 
the PhH, the PsH sub-scales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had a 
greater level of disability and pain, as well as lower HRQoL 
than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 1.9% (1.1–5.1%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices were used for PF items 6, 9, 13, 14, and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 5 (data not shown). The median 
number of items marked as not applicable was 1% (0–1) for 
the PF and 3.5% (2–5%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 86.9% (81.2–90.4%) for the PF 
items, 64.0% (53.5–75.2%) for the HRQoL physical health 
(PhH) items, and 60.2% (57.0–66.2%) for the HRQoL psy-
chosocial health (PsH) items. The median ceiling effect 
was 0.3% (0–1%) for the PF items, 1.9% (1–3.8%) for the 
HRQoL-PhH items, and 2.2% (1.3–2.5%) for the HRQoL-
PsH items. The median floor effect was 34.7% for the pain 
VAS, 32.5% for the disease activity VAS and 31.8% for the 
well-being VAS. The median ceiling effect was 0% for the 
pain VAS, 1.9% for the disease activity VAS, and 0% for the 
well-being VAS.
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Table 1  Descriptive statistics (medians first–third quartiles or absolute frequencies and %) for the 319 JIA patients
Data related to the JAMAR refer to the 314 JIA patients and to the 99 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report; ESR erythrocyte sedimentation rate; MD Medical Doctor; VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity); LOM limitation of motion; ANA anti-nuclear antibodies; PF physical function (total 
score ranges from 0 to 45); HRQoL Health-Related Quality of Life (total score ranges from 0 to 30); PhH Physical Health (total score ranges 
from 0 to 15); PsH Psychosocial Health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF−poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 9 N = 117 N = 75 N = 10 N = 18 N = 65 N = 25 N = 319 N = 100
Female 3 (33.3%) 81 (69.2%) 61 (81.3%) 10 (100%) 11 (61.1%) 26 (40%) 16 (64%) 208 (65.2%)# 62 (62%)
Age at visit 14.4 (12.2–
17.1)
10.6 
(8.3–14.2)
13.2 
(9.6–15.5)
15.8 (13.1–
16.6)
13.6 (9–15.8) 14.2 (12.6–
15.4)
14.1 (12.2–
15.4)
12.8 
(9.7–15.3)#
12.1 
(9.5–13.9)
Age at onset 4.7 (3.2–8.7) 4.2 (2.1–7.9) 9.2 (4.6–11.7) 11.6 
(8.7–13.1)
8 (4.7–10.4) 9.9 (7.7–12.3) 8.2 (3.6–10.5) 7.9 (3.7–
11.1)#
Disease duration 5.7 (2.5–10.1) 3.8 (2.1––7.7) 2.5 (1.4–5.3) 3.9 (2.2–4.4) 3.7 (3.3–5.8) 3.6 (1.3–5) 5.2 (3.3–7.3) 3.7 (1.9–
6.5)*
ESR 8 (5–13) 7.5 (4–11) 10 (5.5–18) 5.5 (4–6) 8.5 (6–20) 5 (3–7) 6.5 (3.5–10) 6 (4–10)*
MD VAS 
(0–10 cm)
0 (0–0) 0.5 (0–1.5) 1.5 (0.5–4) 0.8 (0–2) 0.8 (0–2.5) 0.5 (0–1.5) 0.5 (0–1) 0.5 (0–2)**
No. swollen joints 0 (0–0) 0 (0–1) 1 (0–3) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–1)**
No. joints with 
pain
0 (0–0) 0 (0–1) 0 (0–4) 0 (0–1) 0.5 (0–2) 0 (0–2) 0 (0–2) 0 (0–2)
No. joints with 
LOM
0 (0–2) 1 (0–3) 2 (0–9) 0 (0–1) 1.5 (0–6) 2 (1–3) 3 (2–4) 2 (0–4)**
No. active joints 0 (0–1) 0 (0–1) 1 (0–5) 0 (0–1) 0.5 (0–1) 0 (0–1) 0 (0–2) 0 (0–2)*
Active systemic 
features
0 (0%) 1/111 (0.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1/302 (0.3%)
ANA status 1 (11.1%) 13 (11.1%) 5 (6.7%) 3 (30%) 1 (5.6%) 0 (0%) 3 (12%) 26 (8.2%)
Uveitis 0 (0%) 19/113 
(16.8%)
5 (6.7%) 0 (0%) 2 (11.8%) 2 (3.2%) 1 (4%) 29/312 
(9.3%)*
PF total score 2 (0–3) 0 (0–1) 2 (0–8) 1.5 (0–4) 0 (0–1) 0 (0–1) 0.5 (0–5) 0 (0–3)# 0 (0–0)#
Pain VAS 1 (1–3.5) 0.5 (0–3) 2 (0.5–5.5) 3.5 (1–5) 0.8 (0–3) 1 (0–3) 1.8 (1–4.3) 1 (0–3.5)** 0 (0–0)#
Disease activity 
VAS
1 (0.5–3) 0.5 (0–2) 1.8 (0–4) 2 (1–4) 1 (0–4) 1 (0–2) 0.5 (0–3) 1 (0–3)
Well–being VAS 1.5 (0.5–2.5) 0.5 (0–2) 2 (1–4.5) 0.8 (0–5) 0.5 (0–2.5) 1 (0–2) 1.5 (0–3) 1 (0–3)#
HRQoL-PhH 2 (0–6) 1 (0–3) 2 (1–5) 3 (0–6) 1 (0–3) 1 (0–3) 3 (1–5) 1 (0–4)* 0 (0–0)#
HRQoL-PsH 0 (0–1) 1 (0–4) 2 (0–4) 2.5 (0–4) 1 (0–5) 1 (0–4) 1.5 (1–4) 1 (0–4) 0 (0–2)**
HRQoL total 
score
3 (0–7) 2 (0–8) 4 (1–11) 4 (0–13) 3 (0–7) 3 (0–6) 4.5 (3–8) 3 (0–8) 0 (0–2)#
Pain/swell. in > 1 
joint
1 (11.1%) 44/115 
(38.3%)
50 (66.7%) 6 (60%) 13 (72.2%) 29/63 (46%) 13/24 (54.2%) 156/314 
(49.7%)
5/99 (5.1%)#
Morning stiff-
ness > 15 min
2 (22.2%) 11/110 (10%) 19/74 (25.7%) 2 (20%) 2 (11.1%) 5/63 (7.9%) 6/23 (26.1%) 47/307 
(15.3%)
1/96 (1%)**
Subjective remis-
sion
2 (25%) 42/107 
(39.3%)
53/71 (74.6%) 7/9 (77.8%) 8/17 (47.1%) 30/59 (50.8%) 16/23 (69.6%) 158/294 
(53.7%)
In treatment 7 (77.8%) 78/114 
(68.4%)
70 (93.3%) 9 (90%) 16 (88.9%) 46/62 (74.2%) 17/23 (73.9%) 243/311 
(78.1%)
Reporting side 
effects
0 (0%) 32/76 (42.1%) 31/68 (45.6%) 5/9 (55.6%) 8/15 (53.3%) 12/45 (26.7%) 8/17 (47.1%) 96/237 
(40.5%)
Taking medica-
tion regularly
7/7 (100%) 70/76 (92.1%) 61/68 (89.7%) 8/9 (88.9%) 13/16 
(81.3%)
42/45 (93.3%) 15/17 (88.2%) 216/238 
(90.8%)
With problems 
attending school
3/6 (50%) 10/78 (12.8%) 16/47 (34%) 2/7 (28.6%) 3/12 (25%) 11/51 (21.6%) 6/20 (30%) 51/221 
(23.1%)
0 (0%)#
Satisfied with dis-
ease outcome
9 (100%) 86/106 
(81.1%)
48/74 (64.9%) 5 (50%) 14 (77.8%) 48/58 (82.8%) 16/22 (72.7%) 226/297 
(76.1%)
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Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the 
PF items, with the exception of PF items 9, 11, and 15, and 
for 80% of the HRQoL items, with the exception of HRQoL 
items 1 and 8.
Item internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 93% of items 
of the PF (except for PF item 15) and 100% of items of the 
HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report; JIA juvenile idiophatic arthritis; VAS visual analogue scale; PF physical func-
tion; HRQoL Health-Related Quality of Life; PhH Physical Health; PsH Psychosocial Health; PF-LL PF-lower limbs; PF-HW PF-hand and 
wrist; PF-US PF-upper segment
Parent N = 314/413 Child N = 287/385
Missing values (first–third quartiles) 1.9 (1.1–5.1) 1.4 (0.7–3.8)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF (%) 86.9 86.8
 HRQoL-PhH (%) 64.0 76.3
 HRQoL-PsH (%) 60.2 67.6
 Pain VAS (%) 34.7 33.8
 Disease activity VAS (%) 32.5 35.5
 Well-being VAS (%) 31.8 40.4
Ceiling effect, median
 PF (%) 0.3 0.3
 HRQoL-PhH (%) 1.9 3.1
 HRQoL-PsH (%) 2.2 2.1
 Pain VAS (%) 0.0 0.0
 Disease activity VAS (%) 1.9 1.4
 Well-being VAS (%) 0.0 0.0
Items with equivalent item-scale correlation 80% for PF, 80% for HRQoL 100% for PF, 80% for HRQoL
Items with item-scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.90 0.92
 PF-HW 0.86 0.90
 PF-US 0.78 0.84
 HRQoL-PhH 0.87 0.87
 HRQoL-PsH 0.84 0.84
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intra-class correlation
 PF total score 0.69 0.41
 HRQoL-PhH 0.34 0.33
 HRQoL-PsH 0.28 0.74
Spearman correlation with JIA core-set variables, median
 PF 0.6 0.5
 HRQoL-PhH 0.5 0.4
 HRQoL-PsH 0.4 0.3
 Pain VAS 0.4 0.4
 Disease activity VAS 0.4 0.4
 Well-being VAS 0.4 0.3
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.90 for PF-LL, 0.86 for PF-HW, 
and 0.78 for PF-US. Cronbach’s alpha was 0.87 for 
HRQoL-PhH and 0.84 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 6 days (0–8 days). The intra-class correlation 
coefficients (ICC) for the PF total score showed a substantial 
reproducibility (ICC = 0.69). The ICC for the HRQoL-PhH 
and for the HRQoL-PsH scores showed a fair reproducibility 
(ICC = 0.34 and ICC = 0.28, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.6). The PF total score best correlation was 
observed with the parent global assessment of well-being 
(r = 0.6, p < 0.001). For the HRQoL, the median correla-
tion of the PhH with the JIA core set of outcome variables 
ranged from 0.3 to 0.7 (median = 0.5), whereas for the PsH 
ranged from 0.3 to 0.5 (median = 0.4). The PhH showed the 
best correlation with the parent’s assessment of pain (r = 0.7, 
p < 0.001) and the PsH with the parent global assessment 
of well-being (r = 0.6, p < 0.001). The median correlations 
between the pain VAS, the well-being VAS, and the dis-
ease activity VAS and the physician-centered and labora-
tory measures were 0.4 (0.2–0.5), 0.4 (0.2–0.5), and 0.4 
(0.2–0.5), respectively.
Discussion
In this study, the German version of the JAMAR was cross-
culturally adapted from the original standard English version 
with two forward and two backward translations. According 
to the results of the validation analysis, the German parent 
and patient versions of the JAMAR possess satisfactory psy-
chometric properties. The disease-specific components of 
the questionnaire discriminated well between patients with 
JIA and healthy controls.
Psychometric performances were good for all domains of 
the JAMAR with few exceptions: PF item 15 (“bite a sand-
wich or an apple”) showed a lower items internal consist-
ency. However, the overall internal consistency was good for 
all the domains. Notably, the ICC for the HRQoL-PhH and 
for the HRQoL-PsH scores showed a fair reproducibility. In 
the external validity evaluation, the Spearman’s correlations 
of the PF and HRQoL scores with JIA core-set parameters 
ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the German version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is thus a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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